Boundless Bio (BOLD) Earnings Analysis

Boundless Bio (BOLD) has no confirmed upcoming earnings date. Last quarter (2026-05-08) it missed with EPS -0.6 USD vs -0.51 USD est (-17.6%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -1.01.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BOLD next report earnings?

No confirmed upcoming earnings date is currently scheduled for BOLD. This page updates as the calendar is published.

BOLD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-0.6 USD-0.51 USD-17.6%Miss
2026-03-09-0.58 USD-0.44 USD-31.8%Miss
2025-05-09-0.71 USD-0.68 USD-4.4%Miss
2024-11-07-0.74 USD-0.76 USD+2.6%Beat
2024-08-12-0.77 USD-0.78 USD+1.3%Beat

Beat rate: 2/5 (40%) over reported quarters with consensus data.

BOLD valuation and analyst view

Trailing P/E-1.01
Trailing EPS-2.49895 USD
Price / book0.65
Dividend yield0.00%
Market cap0.06B
Analyst consensusHold (6 buy / 13 hold / 1 sell)

Related research pages

Frequently asked questions

When is Boundless Bio (BOLD)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for BOLD. This page updates as the calendar is published.

Did BOLD beat earnings last quarter?

In its 2026-05-08 report, BOLD posted EPS of -0.6 USD versus a -0.51 USD estimate — a miss of 17.6%.

What is BOLD's earnings track record?

Over the last 5 reported quarters with consensus data, BOLD beat estimates 2 times (40%).

What is BOLD's current P/E ratio and EPS?

BOLD trades at a trailing P/E of -1.01 on trailing EPS of -2.498951220600705 USD.

What do analysts rate BOLD?

Analyst consensus is "Hold" across 20 ratings (0 strong buy, 6 buy, 13 hold, 1 sell, 0 strong sell).